[The long-term evolution of botulinum toxin dosage in the treatment of hemifacial spasms].
García-Torres
M A
MA
Servicio de Neurología, Fundación Jimenez Díaz, Madrid, Spain. maleligarcia@yahoo.es
García-Ruiz Espiga
P J
PJ
D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005152:Facial Muscles / Q000502:physiology; D019569:Hemifacial Spasm / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D009465:Neuromuscular Agents / Q000627:therapeutic use*
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A